No title
The many cases of malignant melanoma and the following relapses after standard-of-care treatment demands inventions on finding new treatment to this cancer disease. One of the reasons for reduced clinical response in melanoma is the downregulation of tumor specific antigens which results in decreased tumor recognition, followed by tumor escape and progression. This study investigated the potential
